

Product Datasheet

Petrelintide

Catalog No. **BP-00002** · CAS **2766385-23-1** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-14**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area	Pathway
Amylin Receptor	Metabolic Disease	GPCR/G Protein Amylin Receptor

Molecular formula	C₁₈₅H₃₀₅N₄₉O₆₁
Molecular weight	4191.6900 (free base)

SEQUENCE

{gGlu-arachidate}-RDGTATKATERLA-
{homoGlu}-FLQRSSF-{Sar}-
A{NMeIle}-LSSTEVGsNT-{Hyp}-NH₂
Bridge: Lactam Asp3-Lys8

DESCRIPTION

Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research.

BIOLOGICAL ACTIVITY

In Vitro

Petrelintide demonstrates agonistic activity against hAMY3R and hCTR in HEK-293 cells, with EC₅₀ of 2.997 and 9.215 nM, respectively.

SOLUBILITY

DMSO : 25 mg/mL

REFERENCES

- [1]. Zong L, et al. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment. J Med Chem. 2025 Jul 24;68(14):14907-14918.
- [2]. BILL V, et al. 1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1661-P.
- [3]. BILL V, et al. 1662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1662-P.
- [4]. JON G, et al. 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing, Diabetes, 2024;73(Supplement_1):1668-P